| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.73▲ | 0.73▲ | 0.73▲ | 0.73▲ | 0.76▼ |
| MA10 | 0.75▼ | 0.75▼ | 0.75▼ | 0.73▲ | 0.87▼ |
| MA20 | 0.76▼ | 0.76▼ | 0.76▼ | 0.75▼ | 1.12▼ |
| MA50 | 0.81▼ | 0.83▼ | 0.84▼ | 0.89▼ | 1.34▼ |
| MA100 | 0.90▼ | 0.93▼ | 0.95▼ | 1.13▼ | 1.17▼ |
| MA200 | 1.12▼ | 1.25▼ | 1.20▼ | 1.33▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | 0.002▲ | 0.002▲ | 0.011▲ | -0.039▼ |
| RSI | 45.087▼ | 44.779▼ | 44.209▼ | 42.461▼ | 37.906▼ |
| STOCH | 32.548 | 34.310 | 34.310 | 33.836 | 11.541▼ |
| WILL %R | -67.400 | -67.400 | -67.400 | -56.397 | -89.865▼ |
| CCI | -45.362 | -25.836 | -25.836 | 23.437 | -103.519▼ |
|
Sunday, March 22, 2026 10:00 PM
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or ...
|
|
Monday, February 09, 2026 11:02 AM
On February 9, 2026, Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced that results from the Phase 1 Trial of CD19-ARTEMIS® T cells (EB103) in patients with aggressive B Cell Non-Hodgkin Lymphoma ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 14/08/26 | 0.7391 | 0.7391 | 0.7391 | 0.7391 | 8,763 |
| 13/08/26 | 0.7201 | 0.74 | 0.7201 | 0.7246 | 15,833 |
| 12/08/26 | 0.7393 | 0.7451 | 0.7201 | 0.7401 | 8,578 |
| 11/08/26 | 0.721 | 0.7443 | 0.69 | 0.7051 | 11,930 |
| 10/08/26 | 0.72 | 0.818 | 0.715 | 0.722 | 24,395 |
| 07/08/26 | 0.7108 | 0.745 | 0.7108 | 0.7225 | 4,978 |
| 06/08/26 | 0.769 | 0.775 | 0.71 | 0.7459 | 13,931 |
| 05/08/26 | 0.795 | 0.80 | 0.7196 | 0.747 | 99,369 |
| 04/08/26 | 0.70 | 0.7447 | 0.70 | 0.704 | 23,785 |
| 03/08/26 | 0.7458 | 0.7467 | 0.6781 | 0.70 | 26,631 |
|
|
||||
|
|
||||
|
|